CA3219760A1 - Venetoclax dosing regimens for use in treating myelodysplastic syndromes in combination with azacitidine - Google Patents

Venetoclax dosing regimens for use in treating myelodysplastic syndromes in combination with azacitidine Download PDF

Info

Publication number
CA3219760A1
CA3219760A1 CA3219760A CA3219760A CA3219760A1 CA 3219760 A1 CA3219760 A1 CA 3219760A1 CA 3219760 A CA3219760 A CA 3219760A CA 3219760 A CA3219760 A CA 3219760A CA 3219760 A1 CA3219760 A1 CA 3219760A1
Authority
CA
Canada
Prior art keywords
count
nadir
baseline
absolute neutrophil
human subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3219760A
Other languages
English (en)
French (fr)
Inventor
John Hayslip
Steve H. KYE
William B. AINSWORTH
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AbbVie Inc
Original Assignee
AbbVie Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AbbVie Inc filed Critical AbbVie Inc
Publication of CA3219760A1 publication Critical patent/CA3219760A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Dermatology (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
CA3219760A 2021-05-11 2022-05-10 Venetoclax dosing regimens for use in treating myelodysplastic syndromes in combination with azacitidine Pending CA3219760A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163201749P 2021-05-11 2021-05-11
US63/201,749 2021-05-11
PCT/US2022/028429 WO2022240786A1 (en) 2021-05-11 2022-05-10 Venetoclax dosing regimens for use in treating myelodysplastic syndromes in combination with azacitidine

Publications (1)

Publication Number Publication Date
CA3219760A1 true CA3219760A1 (en) 2022-11-17

Family

ID=84028499

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3219760A Pending CA3219760A1 (en) 2021-05-11 2022-05-10 Venetoclax dosing regimens for use in treating myelodysplastic syndromes in combination with azacitidine

Country Status (11)

Country Link
US (1) US20220378811A1 (enExample)
EP (1) EP4337183A4 (enExample)
JP (1) JP2024517318A (enExample)
KR (1) KR20240006659A (enExample)
CN (1) CN117642161A (enExample)
AU (1) AU2022273023A1 (enExample)
BR (1) BR112023023677A2 (enExample)
CA (1) CA3219760A1 (enExample)
IL (1) IL308321A (enExample)
MX (1) MX2023013364A (enExample)
WO (1) WO2022240786A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220315555A1 (en) 2009-05-26 2022-10-06 Abbvie Inc. Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3258941A4 (en) * 2015-02-17 2018-09-26 Cantex Pharmaceuticals, Inc. Treatment of cancers and hematopoietic stem cell disorders privileged by cxcl12-cxcr4 interaction
JP7585231B2 (ja) * 2019-04-29 2024-11-18 イミュノジェン， インコーポレイテッド 抗ｃｄ１２３免疫複合体を含む治療的組み合わせ
WO2020257671A1 (en) * 2019-06-20 2020-12-24 Celgene Corporation Azacitidine in combination with venetoclax, gilteritinib, midostaurin or other compounds for treating leukemia or myelodysplastic syndrome
WO2021037933A1 (en) * 2019-08-28 2021-03-04 Astrazeneca Ab Combination of azd2811 nanoparticles, 5-azacitidine and venetoclax for use in the treatment of cancer
PH12022550835A1 (en) * 2019-10-18 2023-07-03 Forty Seven Inc Combination therapies for treating myelodysplastic syndromes and acute myeloid leukemia

Also Published As

Publication number Publication date
IL308321A (en) 2024-01-01
CN117642161A (zh) 2024-03-01
JP2024517318A (ja) 2024-04-19
AU2022273023A1 (en) 2023-11-23
US20220378811A1 (en) 2022-12-01
BR112023023677A2 (pt) 2024-02-20
KR20240006659A (ko) 2024-01-15
EP4337183A1 (en) 2024-03-20
WO2022240786A1 (en) 2022-11-17
MX2023013364A (es) 2023-11-27
EP4337183A4 (en) 2025-04-23

Similar Documents

Publication Publication Date Title
EP4218761A1 (en) Cd70 and venetoclax, a bcl-2 inhibitor, combination therapy for treating acute myeloid leukemia
US8980259B2 (en) Combination therapy
US20260103532A1 (en) Pharmaceutical compositions of humanized anti-cd40 antibodies and uses thereof
KR20220080179A (ko) (R)-2-[3-[4-아미노-3-(2-플루오로-4-페녹시-페닐)피라졸로[3,4-d]피리미딘-1-일]피페리딘-1-카르보닐]-4-메틸-4-[4-(옥세탄-3-일)피페라진-1-일]펜트-2-엔니트릴을 투여하여 면역 혈소판 감소증을 치료하는 방법
AU2013260101A1 (en) Treatment of myelosuppression
US20220370481A1 (en) Venetoclax dosing regimens for use in treating myelodysplastic syndromes in combination with a cyp3a inhibitor and azacitidine
US20220378811A1 (en) Venetoclax dosing regimens for use in treating myelodysplastic syndromes in combination with azacitidine
Gao et al. Targeting CD38 with daratumumab for platelet transfusion refractoriness in aplastic anemia
Bonaros et al. Ten-year follow-up of a prospective, randomized trial of BT563/bb10 versus anti-thymocyte globulin as induction therapy after heart transplantation
Rodríguez Management of the adverse effects of lenalidomide in multiple myeloma
WO2025045766A1 (en) Compositions comprising humanized anti-cd40 antibodies and methods for treating rheumatoid arthritis using the same
HK40106739A (en) Venetoclax dosing regimens for use in treating myelodysplastic syndromes in combination with azacitidine
TW202440120A (zh) 藉由投予（ｒ）－２－［３－［４－胺基－３－（２－氟－４－苯氧基－苯基）吡唑并［３，４－ｄ］嘧啶－１－基］六氫吡啶－１－羰基］－４－甲基－４－［４－（氧雜環丁－３－基）六氫吡𠯤－１－基］戊－２－烯腈治療患有認知障礙的個體之免疫性血小板減少症之方法
Chang et al. Rituximab and CHOP chemotherapy plus GM-CSF for previously untreated diffuse large B-cell lymphoma in the elderly: a Wisconsin oncology network study
HK40106881A (en) Venetoclax dosing regimens for use in treating myelodysplastic syndromes in combination with a cyp3a inhibitor and azacitidine
WO2025208442A1 (en) Methods of treatment of immune thrombocytopenia using sovleplenib
Elter et al. Alemtuzumab: what is the secret to safe therapy
WO2025209478A1 (en) Methods of treatment warm autoimmune hemolytic anemia using sovleplenib
WO2025040080A1 (en) Treatment of esophageal cancer with anti-lag3, anti-pd-1 and chemotherapy
Tyler et al. A Review of Therapeutics for the Treatment of Lupus
WO2025122961A1 (en) Methods for treating neutropenia
JP2025537848A (ja) 多発性硬化症の治療方法
HK40097470A (en) Cd70 and venetoclax, a bcl-2 inhibitor, combination therapy for treating acute myeloid leukemia
HK40079147A (en) Use of multi-target protein kinase inhibitor
Polo Treatment of Glaucoma with the Fixed Combination of Latanoprost 0.005% and Timolol 0.5%

Legal Events

Date Code Title Description
MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD

Year of fee payment: 3

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250409

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250409

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260622

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260625